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MACEAbstract Introduction: C-reactive protein (CRP) value can identify the risk level for acute coro-
nary syndrome (ACS). Ivabradine, a selective inhibitor of the funny current channel, reduces resting
and exercise HR without affecting cardiac contractility or blood pressure.
Aim of work: Evaluate the influence of Ivabradine on long term prevention of major adverse car-
diac events (MACE) using high sensitivity crp (hs CRP).
Methodology: 60 pts were admitted with ACS over the period of 6 months. Cardiac enzymes
were withdrawn on admission and every 6 h thereafter for 24 h then followed up daily for five days
and when indicated. High sensitivity C-reactive protein (hs-CRP) (quantitative value) which was
done on day of admission and repeated for follow up at day 4 and at day 30 patients divided into
two groups each 30 pts: group (A) who received conventional therapy & ivabradine, group (B) who
received conventional therapy only. Ivabradine given within 48 h of admission 5 mg twice daily
upgraded to 7.5 mg twice daily after one week if tolerable Myocardial perfusion imaging (MPI):
Patients were subjected to Technetium99 sesta MIBI Myocardial perfusion imaging (MPI) within
6–8 h after admission and were followed up on day 30 with the same dose of injection using
multi-spect Siemens dual head gamma Camera.
Results: There were significant variances in Hs-CRP value at day 30 in both groups
(P value < 0.001). Patients of group A showed statistically significant lower level of hs-CRP at
day 30 compared to group B (0.7 ± 0.3 mg/dl versus 1.66 ± 0.9 mg/dl; P value < 0.001) but there
was no statistically significant difference between both groups regarding 30 days follow up MACE
(P value 0.552).
78 A. Fouad AbdEl Latif et al.Conclusion: Administration of ivabradine within 48 h of CCU admission decreased hs-CRP level
in patients with acute coronary syndrome (unstable angina) but did not decrease the occurrence of
major cardiac events in ACS patients.
 2015 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Measuring C-reactive protein (CRP) can identify the risk level
for acute coronary syndrome (ACS). Likewise; reduced heart
rate variability has been demonstrated to be the strongest inde-
pendent predictor of progression of local coronary atheroscle-
rosis [1].
Funny current channels (If), are activated during the rest-
ing potential stage and accelerate diastolic depolarization of
the sinus node and thus its pacemaker function [2]. Ivabra-
dine, a selective inhibitor of the funny current channel,
reduces resting and exercise HR without affecting cardiac
contractility or blood pressure. It exerts antianginal and
anti-ischemic effects in patients with coronary artery disease.
Improved exercise tolerance, increased time to exercise-
induced ischemia, and reduced frequency of ambient anginal
attacks have been observed after funny current channel
inhibition [2].
1. We aimed to evaluate the influence of Ivabradine on long
term prevention of major adverse cardiac events (MACE)
major adverse cardiac events (MACE) including; death,
myocardial infarction, serious arrhythmias, need for urgent
revascularization using high sensitivity crp (hs CRP).
2. Patients
We studied sixty patients admitted to the CCU of critical care
department at Cairo University due to acute coronary syn-
drome over the period of 6 months. All patients gave informed
consent, and the protocol was approved by the institutional
review board.
 Inclusion criteria
 Patients with ischemic manifestations suspected to repre-
sent ACS (unstable angina).
 Patients with sinus rhythm whose heart rate was greater
than 60 beats per minute on a resting standard 12 lead
ECG.
 Exclusion criteria
 Pregnant or breast-feeding women or women of child
bearing potential.
 Patients with acute ST segment elevation or non-ST seg-
ment elevation myocardial infarction or those requiring
urgent coronary revascularization.
 Patients with atrial fibrillation or flutter, sick sinus syn-
drome, sino-atrial block and complete atrio-ventricular
block.3. Methods
All included patients were subjected to:
 Detailed history taking and physical examination: including
Laboratory investigations: (cardiac enzymes and troponin i)
which were withdrawn on admission and every 6 h thereafter
for 24 h then followed up daily for 5 days andwhen indicated.
 High sensitivity C-reactive protein (hs-CRP) (quantitative
value) which was done on day of admission and repeated
for follow up at day 4 and at day 30 (after withdrawal of
study medications) with a normal range <0.5 mg/dl [3].
Eventually, patients were allocated randomly to the follow-
ing groups:
 Group (A): Included thirty patients who received conven-
tional therapy and ivabradine.
 Group (B): Included thirty patients who received conven-
tional therapy only.
Patients of both groups received the conventional cardio-
vascular treatment which included nitrates, maximum toler-
ated dose of beta blocker (bisoprolol 10 mg/day), statins
(atorvastatin 40 mg/day), antiplatelets (ASA 150 mg/day).
Ivabradine administration protocol for patients of group
(A): included;
 Within 48 h of hospital admission, the starting dose of ivab-
radine was 5 mg twice daily.
 After one week, patients with resting heart rate greater than
60 beats per minute received the target dose of 7.5 mg of
ivabradine twice daily up to the follow up period of 30 days.
 cardiac assessment:
 Electrocardiography (ECG).
 Echocardiography (TTE).
 Myocardial perfusion imaging (MPI).
Patients were subjected to Technetium99 sesta MIBI
Myocardial perfusion imaging (MPI) within 6–8 h after admis-
sion as an acute imaging equivalent to stress MPI then after
4 days as rest MPI and were followed up on day 30 with rest
and stress imaging with the same dose of injection using
multi-spect Siemens dual head gamma Camera.
Statistical methods
All obtained data were analyzed statistically by SPSS (Statisti-
cal Package for Social Science) program.
Table 2 Risk factors for CAD in study population.
Risk factors for CAD Frequency Percentage (%)
HTN 36 60
DM 26 43.3
Smoking 32 53.3
Dyslipidemia 30 50
Obesity 32 53.3
+positive family history of CAD 25 41.7
Table 3 Study population’s characteristics (mean and stan-
dard deviation).
Population’s characteristics Mean ± SD
Age 53.45 ± 7.84
BMI 29.99 ± 5.12
MAP (mmHg) 73.87 ± 9.01
Pulse (bpm) 94.73 ± 20.02
Hs-CRP on admission 1.34 ± 0.39
SSS on day 1 9.82 ± 2.88
SRS on day 4 4.95 ± 2.01
SDS day 1- day 4 4.87 ± 2.13
LVEF stress on day 1 57.95 ± 4.90
LVEF rest on day 4 53.30 ± 5.34
LVEDD stress on day 1 160.98 ± 36.73
LVESD stress on day 1 67.07 ± 14.62
LVEDD rest on day 4 129.22 ± 32.60
LVESD rest on day 4 59.83 ± 14.62
Hs-CRP at day 5 1.23 ± 0.48
Hs-CRP at day 30 1.18 ± 0.83
SSS at day 30 7.00 ± 2.37
SRS at day 30 5.02 ± 2.05
SDS at day 30 1.98 ± 1.51
LVEF stress F/U at day 30 57.08 ± 4.58
LVEF rest F/U at day 30 52.58 ± 5.23
LVEDD stress F/U at day 30 160.20 ± 41.50
LVESD stress F/U at day 30 67.60 ± 14.61
LVEDD rest F/U at day 30 130.27 ± 37.49
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The mean age of the study group was 53.45 years old. In our
study, there were 24 male patients who represented 40% of
study population and 36 female patients which represented
60% of study population (see Table 1).
Our studied patients’ characteristics are summarized in
Table 2.
4.1. Myocardial perfusion imaging (MPI)
 There were no significant differences between both groups
in prevalence of Risk factors; Systemic hypertension
(P value 0.430), Diabetes mellitus (P value 0.435), Smoking
(P value 0.796), dyslipidemia (P valve 1.0), family history of
CAD (P value 0.601) and obesity (P value 0.968).
 There were no significant differences between both groups
in ECG ischemic or dynamic changes (see Tables 3 and 4).
4.1.1 Hs-CRP
 There were significant differences between both groups in
Hs-CRP value on admission and day 4 follow up (P value
0.629, 0.042 respectively).
 There were no significant differences in Hs-CRP value
between admission day and day 4 in patients of group (B)
(P value 0.774).
 There were no significant differences in Hs-CRP value
between day 4 and day 30 in patients of group (B) (P value
0.062).
 There were significant variances in Hs-CRP value at day 4
in both groups; patients in group A showed a statistically
significant lower level of hs-CRP at day 4 compared to
group B (1 ± 0.4 mg/dl versus 1.3 ± 0.5 mg/dl; P value
0.043).Table 1 Demographic data of study group.
Risk factors Group A Group B P value
Frequency (%) Frequency (%)
HTN 20 66.6 16 53 0.430
DM 15 50 11 36.6 0.435
Smoking 17 56.6 15 50 0.796
Dyslipidemia 15 50 15 50 1.000
+positive family
history of CAD
14 46.6 11 36.6 0.601
Obesity (BMI) Mean ± SD Mean ± SD
30 ± 5.1 30 ± 5.2 0.968
Hs-CRP on
admission
1.3 ± 0.4 1.37 ± 0.38 0.629
Hs-CRP at day 4 1.00 ± 0.50 1.34 ± 0.44 0.043
Hs-CRP at day
30
0.7 ± 0.3 1.66 ± 0.9 <0.001
Baseline heart
rate
85 85 1.0
Heart rate on day
30
60 60 1.0
LVESD rest F/U at day 30 60.63 ± 14.69 There were significant variances in Hs-CRP value at day 30
in both groups (P< 0.001). Patients of group A showed
statistically significant lower level of hs-CRP at day 30 com-
pared to group B (0.7 ± 0.3 mg/dl versus 1.66 ± 0.9 mg/dl;
P value < 0.001).
 There were significant differences in Hs-CRP value between
admission day and day 30 in patients of group (A)
(P value < 0.001). Patients of group A showed a signifi-
cantly lower hs-CRP level at day 30 compared to hs-CRP
on admission (0.71 ± 0.28 mg/dl versus 1.32 ± 0.41 mg/
dl; P value < 0.001).
 There were significant variances in Hs-CRP value between
admission day and day 30 in patients of group (B) (P value
0.043). Patients of group B showed a significantly higher
hs-CRP level at day 30 compared to admission hs-CRP
(1.37 ± 0.38 mg/dl versus 1.66 ± 0.92 mg/dl;P value 0.043).
 There were significant variances in Hs-CRP value between
day 4 and day 30 in patients of group (A) (P value 0.001).
Patients of group A showed a significantly lower hs-CRP
at day 30 compared to day 4 (0.71 ± 0.28 mg/dl versus 1
± 0.5 mg/dl; P value 0.001).
Table 4 Territory of myocardial ischemia in MPI of study
population.
Territory of myocardial
ischemia
Frequency Percentage (%)
LAD territory 27 45
LCx territory 9 15
RCA territory 9 15
LAD and LCx territories 5 8.3
LAD and RCA territories 4 6.6
Three-vessel territory (LAD,
LCx and RCA)
6 10
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 There were no significant differences between both groups
in territorial myocardial perfusion defects (P value 0.668).
 There were no statistically significant differences in summed
stress score (SSS) on admission and on day 30 between both
groups (P value 0.894 and 0.194 respectively).
 There were no statistically significant differences in left ven-
tricular end-systolic volume (LVESV) during stress at day
30 between both groups (P value 0.714) (see Table 5).
By following up the trend of hs-CRP quantitative value on
day 1, day 4 and day 30 in both groups of patients, we found
that those who received ivabradine together with conventional
therapy (group A) showed decreasing value of hs-CRP during
one month follow up period which was not observed in those
who received conventional therapy only without ivabradine
(group B) (P value < 0.001).
4.2. Mortality data
Although, MACE occurred in 15 patients (25% of study pop-
ulation) during follow up after one month, there was no statis-
tically significant difference between both groups regarding
30 days follow up MACE (P value 0.552).
5. Discussion
Although serum concentrations of cardiac enzymes are the
main diagnostic laboratory investigation of acute coronary
syndrome, serum concentration of inflammatory markers has
shown in many studies to correlate strongly with cardiovascu-
lar mortality & morbidity in patients with acute coronary syn-
drome [4].Table 5 Myocardial perfusion defects of both groups.
Myocardial perfusion defects
Single defect (single-vessel disease) LAD territory
LCX territory
RCA territory
Two defects (two-vessel disease) LAD and LCX territorie
LAD and RCA territori
Three defects (three-vessel disease)Measuring serum C-reactive protein level (CRP) with the
improved methodology of the highly sensitive assay can iden-
tify the risk level for acute coronary syndrome (ACS) [3].
Ivabradine, a selective inhibitor of the funny current chan-
nel, reduces resting and exercise heart rate without affecting
cardiac contractility or blood pressure. It exerts antianginal
and anti-ischemic effects in patients with coronary artery dis-
ease. Improved exercise tolerance and reduced frequency of
anginal attacks have been observed after funny current chan-
nel inhibition [2].
Reduced heart rate variability and increased resting heart
rate are indicators of sympatho-vagal defect and has been
found to be associated with cardiovascular mortality and mor-
bidity in patients with acute coronary syndrome [5]. It has been
also shown to be a potent indicator of progression of coronary
artery disease [1]. This has been associated with coronary pla-
que rupture with sub-clinical inflammation and plays a role in
the pathogenesis of coronary atherosclerosis [6].
Through comparison between the two groups of studied
patient, Group A who received ivabradine together with con-
ventional anti-ischemic therapy and group B who received con-
ventional anti-ischemic therapy only; there were no significant
differences between both groups regarding age, gender, preva-
lence of risk factors, ischemic ECG changes and hs-CRP level
on day of admission (P value > 0.05).
Our current study showed significant variances in hs-CRP
value at day 4 and day 30 in both groups, patients of group
A showed a statistically significant lower level of hs-CRP at
day 4 and day 30 compared to group B (P value 0.043 and
<0.001 respectively). Also there were significant differences
in Hs-CRP level of group A between admission day and day
30 (P value < 0.001) and between day 4 and day 30 (P value
0.001).Patients of group A showed a significantly lower hs-
CRP level at day 30 compared to hs-CRP on admission and
on day 4.
In concordance with our findings, a randomized, double-
blind, placebo-controlled trial of ivabradine in patients with
NSTE-ACS that was carried out by Alberto et al. in April
2012 and published in June 2012 in the international journal
of cardiology. They hypothesized that the addition of ivabra-
dine (a heart rate lowering agent) to standard medical therapy
had a beneficial effect on markers of inflammatory stress in
acute coronary syndrome patients using high sensitivity C-
reactive protein as an independent factor for sub-clinical
inflammatory state [4].
In contrast, Alberto et al. disagreed with our study by
demonstrating that higher hs-CRP levels were associated with
adverse outcomes and that HR reduction with ivabradine has
been shown to decrease major adverse cardiovascular events.
They stated that this effect was related to decreasing serum
levels of markers of vascular oxidative stress, improvingGroup A Group B P value
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mation [4].
Supporting our results, the Riviera study, a uni-center, ran-
domized, double-blind, placebo-controlled trial involving 1270
patients admitted with non-ST elevation ACS, hypothesized
that early initiation of ivabradine therapy after hospital admis-
sion for ACS led to reduction of hs-CRP levels [8]. In contrast,
the Riviera study stated that immediate administration of
ivabradine therapy after hospital admission for ACS was asso-
ciated with improvement of cardiovascular outcomes [7].
Our study showed that there was no statistically significant
difference between both groups regarding 30 days follow up
MACE (P value 0.552).
These findings agreed with the study of Shavarov et al. that
was conducted on 98 unstable angina patients with 14 days fol-
low up and investigated the efficacy of early administration of
ivabradin in addition to metoprolol in patients with acute
coronary syndrome (unstable angina) compared to the efficacy
of administration of metoprolol alone. They concluded that
combined treatment with metoprolol and ivabradine showed
the same anti-ischemic activity compared with metoprolol reg-
imen in patients with ACS. There were no significant differ-
ences in occurrence of major adverse cardiovascular events in
both groups of patients (P value 0.14) [8].
Unfortunately, our study was conducted on sixty patients
only, being a self-funding research with lack of the quantitative
hs-CRP in our CCU laboratory unit. In addition, our study
included follow up of hs-CRP for all studied patients on day
1, at day 4 and at day 30.
The high selectivity of our studied patients limited their
number. This was essential for the accuracy of our results.
We excluded any patient above the age of 80 years, dissemi-
nated malignancies, chronic liver cell failure, patients with
chronic renal dialysis, chronic hematological disorders,
patients with coagulation defects or receiving anti-
coagulation therapy, concomitant treatment with carcinostat-
ics or irradiation, post-cardiopulmonary resuscitation status,
those whose investigations could not be done or lost, patients
transferred to other hospitals, missing values of any included
patient.
Finally, concerning the statistically insignificant results con-
cerning the effect of Ivabradine which were observed in our
study, it would be better to be revised and re-evaluated againin future studies on a larger number of patients to give more
accurate statistical results.
6. Conclusion
Administration of ivabradine within 48 h of CCU admission
decreased hs-CRP level in patients with acute coronary syn-
drome (unstable angina).but did not decrease the occurrence
of major cardiac events in ACS patients.
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